{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:22:27Z","timestamp":1792023747406,"version":"4.4.0"},"reference-count":105,"publisher":"European Respiratory Society (ERS)","issue":"5","content-domain":{"domain":["ersjournals.com"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:p>Idiopathic pulmonary fibrosis (IPF) remains a truly idiopathic fibrotic disease, with a modest genetic predilection and candidate triggers but no overall explanation for the development of disease in non-familial cases. Agreement on terminology has contributed to major clinical and translational advances since the millennium. It is likely that the entity currently captured by the term \u201cIPF\u201d will be radically reclassified over the next decade, either through \u201csplitting\u201d (into IPF subgroups responding selectively to individual disease-modifying agents) or through \u201clumping\u201d of IPF with other forms of progressive fibrotic lung disease (with shared pathogenetic mechanisms and IPF-like disease behaviour). In this perspective, we summarise the clinical and pathogenetic justification for a focus on \u201cthe progressive fibrotic phenotype\u201d in future clinical and translational research. By this means, we can hope to address the needs of non-IPF patients with inexorably progressive fibrotic disease, currently disenfranchised by lack of access to agents that are efficacious in IPF. In this regard, ongoing trials of anti-fibrotic therapies in non-IPF patients with progressive fibrosis may be highly influential. Future revision of IPF nomenclature may be warranted if there are major conceptual changes but without compelling justification, the benefits of renaming IPF are likely to be outweighed by the resulting confusion.<\/jats:p>","DOI":"10.1183\/13993003.00692-2018","type":"journal-article","created":{"date-parts":[[2018,5,17]],"date-time":"2018-05-17T03:40:11Z","timestamp":1526528411000},"page":"1800692","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":297,"title":["What's in a name? That which we call IPF, by any other name would act the same"],"prefix":"10.1183","volume":"51","author":[{"given":"Athol U.","family":"Wells","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin R.","family":"Flaherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor\u00a0J.","family":"Thannickal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2018,5,17]]},"reference":[{"key":"2019031507240320000_51.5.1800692.1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.2.ats01"},{"key":"2019031507240320000_51.5.1800692.2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.157.1.9704130"},{"key":"2019031507240320000_51.5.1800692.3","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.2009-040GL"},{"key":"2019031507240320000_51.5.1800692.4","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201512-2544CP"},{"key":"2019031507240320000_51.5.1800692.5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S2213-2600(18)30007-9","article-title":"Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic","volume":"6","author":"Wolters","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2019031507240320000_51.5.1800692.6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/S2213-2600(18)30022-5","article-title":"Idiopathic pulmonary fibrosis: idiopathic no more?","volume":"6","author":"Thannickal","year":"2018","journal-title":"Lancet Respir Med"},{"key":"2019031507240320000_51.5.1800692.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013660"},{"key":"2019031507240320000_51.5.1800692.8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-2-200101160-00015"},{"key":"2019031507240320000_51.5.1800692.9","doi-asserted-by":"publisher","DOI":"10.1172\/JCI74368"},{"key":"2019031507240320000_51.5.1800692.10","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0122-2016"},{"key":"2019031507240320000_51.5.1800692.11","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00398-2016"},{"key":"2019031507240320000_51.5.1800692.12","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2014-206411"},{"key":"2019031507240320000_51.5.1800692.13","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.4.2592"},{"key":"2019031507240320000_51.5.1800692.14","doi-asserted-by":"crossref","first-page":"e0127771","DOI":"10.1371\/journal.pone.0127771","article-title":"Autoantibody-targeted treatments for acute exacerbations of idiopathic pulmonary fibrosis","volume":"10","author":"Donahoe","year":"2015","journal-title":"PLoS One"},{"key":"2019031507240320000_51.5.1800692.15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI66700"},{"key":"2019031507240320000_51.5.1800692.16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI71386"},{"key":"2019031507240320000_51.5.1800692.17","doi-asserted-by":"crossref","first-page":"231ra47","DOI":"10.1126\/scitranslmed.3008182","article-title":"Reversal of persistent fibrosis in aging by targeting Nox4-Nrf2 redox imbalance","volume":"6","author":"Hecker","year":"2014","journal-title":"Sci Transl Mede"},{"key":"2019031507240320000_51.5.1800692.18","doi-asserted-by":"publisher","DOI":"10.1038\/srep37445"},{"key":"2019031507240320000_51.5.1800692.19","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201308-1483ST"},{"key":"2019031507240320000_51.5.1800692.20","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2609"},{"key":"2019031507240320000_51.5.1800692.21","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201505-1010OC"},{"key":"2019031507240320000_51.5.1800692.22","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201101-0058OC"},{"key":"2019031507240320000_51.5.1800692.23","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2013-204596"},{"key":"2019031507240320000_51.5.1800692.24","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201505-0992OC"},{"key":"2019031507240320000_51.5.1800692.25","doi-asserted-by":"crossref","first-page":"e91377","DOI":"10.1172\/jci.insight.91377","article-title":"3D pulmospheres serve as a personalized and predictive multicellular model for assessment of antifibrotic drugs","volume":"2","author":"Surolia","year":"2017","journal-title":"JCI Insight"},{"key":"2019031507240320000_51.5.1800692.26","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201505-0862OC"},{"key":"2019031507240320000_51.5.1800692.27","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2016-209172"},{"key":"2019031507240320000_51.5.1800692.28","doi-asserted-by":"publisher","DOI":"10.1136\/jmedgenet-2016-103973"},{"key":"2019031507240320000_51.5.1800692.29","doi-asserted-by":"publisher","DOI":"10.1097\/MCP.0000000000000187"},{"key":"2019031507240320000_51.5.1800692.30","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S2213-2600(17)30348-X","article-title":"Personalised medicine for IPF: getting closer, but not there yet","volume":"5","author":"Sato","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2019031507240320000_51.5.1800692.31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1105185"},{"key":"2019031507240320000_51.5.1800692.32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1403291"},{"key":"2019031507240320000_51.5.1800692.33","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"2019031507240320000_51.5.1800692.34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1106469"},{"key":"2019031507240320000_51.5.1800692.35","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2213-2600(16)30265-X","article-title":"Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials","volume":"4","author":"Hanania","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2019031507240320000_51.5.1800692.36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0050093"},{"key":"2019031507240320000_51.5.1800692.37","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201203-0506OC"},{"key":"2019031507240320000_51.5.1800692.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402582"},{"key":"2019031507240320000_51.5.1800692.39","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1164\/rccm.201602-0402OC","article-title":"Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria","volume":"195","author":"Raghu","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2019031507240320000_51.5.1800692.40","unstructured":"Wells AU . Approach to diagnosis of diffuse lung disease. In: Albert RK , Spiro SG , Jett JR , eds. Clinical Respiratory Medicine. 2nd Edn. Mosby, Elsevier Science, 2004."},{"key":"2019031507240320000_51.5.1800692.41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055120"},{"key":"2019031507240320000_51.5.1800692.42","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"key":"2019031507240320000_51.5.1800692.43","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121043"},{"key":"2019031507240320000_51.5.1800692.44","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.chest.2016.10.029","article-title":"Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis","volume":"151","author":"Morisset","year":"2017","journal-title":"Chest"},{"key":"2019031507240320000_51.5.1800692.45","doi-asserted-by":"crossref","first-page":"00016\u20132017","DOI":"10.1183\/23120541.00016-2017","article-title":"Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis","volume":"3","author":"Adegunsoye","year":"2017","journal-title":"ERJ Open Res"},{"key":"2019031507240320000_51.5.1800692.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.11.026"},{"key":"2019031507240320000_51.5.1800692.47","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.chest.2017.02.011","article-title":"Pathologic findings and prognosis in a large prospective cohort of chronic hypersensitivity pneumonitis","volume":"152","author":"Wang","year":"2017","journal-title":"Chest"},{"key":"2019031507240320000_51.5.1800692.48","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/148.1.49"},{"key":"2019031507240320000_51.5.1800692.49","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2004.027326"},{"key":"2019031507240320000_51.5.1800692.50","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e3181bb2538"},{"key":"2019031507240320000_51.5.1800692.51","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-012-2427-0"},{"key":"2019031507240320000_51.5.1800692.52","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200607-912OC"},{"key":"2019031507240320000_51.5.1800692.53","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00019210"},{"key":"2019031507240320000_51.5.1800692.54","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12931-014-0154-6","article-title":"Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia","volume":"15","author":"Moua","year":"2014","journal-title":"Respir Res"},{"key":"2019031507240320000_51.5.1800692.55","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2012.04.004"},{"key":"2019031507240320000_51.5.1800692.56","first-page":"103","article-title":"Clinical course and outcome of rheumatoid arthritis-related usual interstitial pneumonia","volume":"30","author":"Song","year":"2013","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2019031507240320000_51.5.1800692.57","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00092309"},{"key":"2019031507240320000_51.5.1800692.58","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu165"},{"key":"2019031507240320000_51.5.1800692.59","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00357-2015"},{"key":"2019031507240320000_51.5.1800692.60","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.rmed.2017.03.027","article-title":"High resolution computed tomography pattern of usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease: Relationship to survival","volume":"126","author":"Yunt","year":"2017","journal-title":"Respir Med"},{"key":"2019031507240320000_51.5.1800692.61","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.rmed.2017.11.013","article-title":"Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease","volume":"134","author":"Nurmi","year":"2018","journal-title":"Respir Med"},{"key":"2019031507240320000_51.5.1800692.62","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00150-2015"},{"key":"2019031507240320000_51.5.1800692.63","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01565-2015"},{"key":"2019031507240320000_51.5.1800692.64","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.13130187"},{"key":"2019031507240320000_51.5.1800692.65","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.rmed.2017.07.007","article-title":"Unclassifiable-interstitial lung disease: Outcome prediction using CT and functional indices","volume":"130","author":"Jacob","year":"2017","journal-title":"Respir Med"},{"key":"2019031507240320000_51.5.1800692.66","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00131912"},{"key":"2019031507240320000_51.5.1800692.67","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2003.10.015"},{"key":"2019031507240320000_51.5.1800692.68","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200210-1245OC"},{"key":"2019031507240320000_51.5.1800692.69","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200403-331OC"},{"key":"2019031507240320000_51.5.1800692.70","doi-asserted-by":"publisher","DOI":"10.1378\/chest.120.2.617"},{"key":"2019031507240320000_51.5.1800692.71","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00187410"},{"key":"2019031507240320000_51.5.1800692.72","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210035"},{"key":"2019031507240320000_51.5.1800692.73","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2019031507240320000_51.5.1800692.74","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00115.2016"},{"key":"2019031507240320000_51.5.1800692.75","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4035"},{"key":"2019031507240320000_51.5.1800692.76","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02314-2016"},{"key":"2019031507240320000_51.5.1800692.77","doi-asserted-by":"crossref","first-page":"e0189467","DOI":"10.1371\/journal.pone.0189467","article-title":"Short telomere length in IPF lung associates with fibrotic lesions and predicts survival","volume":"12","author":"Snetselaar","year":"2017","journal-title":"PLoS One"},{"key":"2019031507240320000_51.5.1800692.78","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S2213-2600(17)30216-3","article-title":"The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study","volume":"5","author":"Ley","year":"2017","journal-title":"Lancet Respir Med"},{"key":"2019031507240320000_51.5.1800692.79","first-page":"228","article-title":"Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis","volume":"32","author":"Kennedy","year":"2015","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2019031507240320000_51.5.1800692.80","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000219"},{"key":"2019031507240320000_51.5.1800692.81","doi-asserted-by":"publisher","DOI":"10.1007\/s10522-013-9451-6"},{"key":"2019031507240320000_51.5.1800692.82","first-page":"7","article-title":"Epithelial stem cell exhaustion in the pathogenesis of idiopathic pulmonary fibrosis","volume":"27","author":"Chilosi","year":"2010","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"2019031507240320000_51.5.1800692.83","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pharmthera.2017.10.005","article-title":"Mitochondria, telomeres and cell senescence: Implications for lung ageing and disease","volume":"183","author":"Birch","year":"2018","journal-title":"Pharmacol Ther"},{"key":"2019031507240320000_51.5.1800692.84","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-201786"},{"key":"2019031507240320000_51.5.1800692.85","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.5827"},{"key":"2019031507240320000_51.5.1800692.86","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(13)70045-6"},{"key":"2019031507240320000_51.5.1800692.87","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12890-017-0462-y","article-title":"Exploring efficacy and safety of oral pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial","volume":"17","author":"Behr","year":"2017","journal-title":"BMC Pulm Med"},{"key":"2019031507240320000_51.5.1800692.88","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000212"},{"key":"2019031507240320000_51.5.1800692.89","first-page":"154","article-title":"Fulminating diffuse interstitial fibrosis of the lungs","volume":"51","author":"Hamman","year":"1935","journal-title":"Trans Am Clin Climat Assoc"},{"key":"2019031507240320000_51.5.1800692.90","unstructured":"Liebow AA . New concepts and entities in pulmonary disease. In: Liebow AA , Smith DE , eds. The Lung. Baltimore, The Williams and Wilkins Company; 1968; pp. 332\u2013365."},{"key":"2019031507240320000_51.5.1800692.91","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197804132981501"},{"key":"2019031507240320000_51.5.1800692.92","doi-asserted-by":"publisher","DOI":"10.1378\/chest.80.3.259"},{"key":"2019031507240320000_51.5.1800692.93","first-page":"382","article-title":"Cryptogenic organizing pneumonitis","volume":"52","author":"Davison","year":"1983","journal-title":"Q J Med"},{"key":"2019031507240320000_51.5.1800692.94","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198501173120304"},{"key":"2019031507240320000_51.5.1800692.95","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198401193100304"},{"key":"2019031507240320000_51.5.1800692.96","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/00000478-198907000-00006","article-title":"Giant-cell interstitial pneumonia and hard-metal pneumoconiosis. a clinicopathologic study of four cases and review of the literature","volume":"13","author":"Ohori","year":"1989","journal-title":"Am J Surg Pathol"},{"key":"2019031507240320000_51.5.1800692.97","first-page":"95","article-title":"Development and use of a pneumoconiosis database of human pulmonary inorganic particulate burden in over 400 lungs","volume":"5","author":"Abraham","year":"1991","journal-title":"Scanning Microsc"},{"key":"2019031507240320000_51.5.1800692.98","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-199402000-00003"},{"key":"2019031507240320000_51.5.1800692.99","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.161.2.ats3-00"},{"key":"2019031507240320000_51.5.1800692.100"},{"key":"2019031507240320000_51.5.1800692.101","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00021005"},{"key":"2019031507240320000_51.5.1800692.102","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066157"},{"key":"2019031507240320000_51.5.1800692.103","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402584"},{"key":"2019031507240320000_51.5.1800692.104","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201506-1063ST"},{"key":"2019031507240320000_51.5.1800692.105","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S2213-2600(17)30433-2","article-title":"Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper","volume":"6","author":"Lynch","year":"2018","journal-title":"Lancet Respir Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.00692-2018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T01:57:44Z","timestamp":1740362264000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.00692-2018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":105,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,5,17]]},"published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1183\/13993003.00692-2018"],"URL":"https:\/\/doi.org\/10.1183\/13993003.00692-2018","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]}}}